185 related articles for article (PubMed ID: 25913481)
1. Apolipoproteins A1, B, and other prognostic biochemical cardiovascular risk factors in patients with beta-thalassemia major.
Ghorban K; Shanaki M; Mobarra N; Azad M; Asadi J; Pakzad R; Ehteram H
Hematology; 2016 Mar; 21(2):113-20. PubMed ID: 25913481
[TBL] [Abstract][Full Text] [Related]
2. Combined use of apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol before routine clinical lipid measurement in predicting coronary heart disease.
Pan L; Lu G; Chen Z
Coron Artery Dis; 2014 Aug; 25(5):433-8. PubMed ID: 24608795
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of lipids and lipoproteins in Syrian patients with beta-thalassemia major.
Al-Quobaili FA; Abou Asali IE
Saudi Med J; 2004 Jul; 25(7):871-5. PubMed ID: 15235691
[TBL] [Abstract][Full Text] [Related]
4. Prooxidant-antioxidant balance and hs-CRP in patients with beta-thalassemia major.
Ehteram H; Bavarsad MS; Mokhtari M; Saki N; Soleimani M; Parizadeh SM; Mobarra N
Clin Lab; 2014; 60(2):207-15. PubMed ID: 24660532
[TBL] [Abstract][Full Text] [Related]
5. Apolipoprotein B/apolipoprotein A1 ratio and non-high-density lipoprotein cholesterol. Predictive value for CHD severity and prognostic utility in CHD patients.
Liting P; Guoping L; Zhenyue C
Herz; 2015 Mar; 40 Suppl 1():1-7. PubMed ID: 25374385
[TBL] [Abstract][Full Text] [Related]
6. Apolipoproteins A1, B, and apoB/apoA1 ratio are associated with first ST-segment elevation myocardial infarction but not with recurrent events during long-term follow-up.
Bodde MC; Hermans MPJ; Jukema JW; Schalij MJ; Lijfering WM; Rosendaal FR; Romijn FPHTM; Ruhaak LR; van der Laarse A; Cobbaert CM
Clin Res Cardiol; 2019 May; 108(5):520-538. PubMed ID: 30298424
[TBL] [Abstract][Full Text] [Related]
7. The apoB/apoA1 ratio predicts future cardiovascular events in patients with rheumatoid arthritis.
Öhman M; Öhman ML; Wållberg-Jonsson S
Scand J Rheumatol; 2014; 43(4):259-64. PubMed ID: 24689997
[TBL] [Abstract][Full Text] [Related]
8. Association between C-reactive protein, pro-oxidant-antioxidant balance and traditional cardiovascular risk factors in an Iranian population.
Razavi A; Baghshani MR; Rahsepar AA; Mohaddes Ardabili H; Sheikh Andalibi MS; Reza Parizadeh SM; Tavallaie S; Mousavi S; Ghayour-Mobarhan M; Ferns G
Ann Clin Biochem; 2013 Mar; 50(Pt 2):115-21. PubMed ID: 23440541
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular disease risk associated with serum apolipoprotein B is modified by serum vitamin A.
Olsen T; Vinknes KJ; Svingen GFT; Pedersen ER; Tell GS; Blomhoff R; Drevon CA; Ueland PM; Midttun Ø; Refsum H; Nygård OK
Atherosclerosis; 2017 Oct; 265():325-330. PubMed ID: 28774484
[TBL] [Abstract][Full Text] [Related]
10. Dietary, macronutrient, micronutrient, and nutrigenetic factors impacting cardiovascular risk markers apolipoprotein B and apolipoprotein A1: a narrative review.
Nacarelli GS; Fasolino T; Davis S
Nutr Rev; 2024 Jun; 82(7):949-962. PubMed ID: 37615981
[TBL] [Abstract][Full Text] [Related]
11. Effects of Iron Supplementation With and Without Docosahexaenoic Acid on the Cardiovascular Disease Risk Based on Paraoxonase-1, hs-CRP, and ApoB/ApoA-I Ratio in Women with Iron Deficiency Anemia.
Shidfar F; Amani S; Vafa M; Shekarriz R; Hosseini S; Shidfar S; Eshraghian M; Mousavi SN
Biol Trace Elem Res; 2016 Jan; 169(1):34-40. PubMed ID: 26077874
[TBL] [Abstract][Full Text] [Related]
12. Computationally estimated apolipoproteins B and A1 in predicting cardiovascular risk.
Raitakari OT; Mäkinen VP; McQueen MJ; Niemi J; Juonala M; Jauhiainen M; Salomaa V; Hannuksela ML; Savolainen MJ; Kesäniemi YA; Kovanen PT; Sundvall J; Solakivi T; Loo BM; Marniemi J; Hernesniemi J; Lehtimäki T; Kähönen M; Peltonen M; Leiviskä J; Jula A; Anand SS; Miller R; Yusuf S; Viikari JS; Ala-Korpela M
Atherosclerosis; 2013 Jan; 226(1):245-51. PubMed ID: 23159013
[TBL] [Abstract][Full Text] [Related]
13. The graded relationship between glucose tolerance status in pregnancy and postpartum levels of low-density-lipoprotein cholesterol and apolipoprotein B in young women: implications for future cardiovascular risk.
Retnakaran R; Qi Y; Connelly PW; Sermer M; Hanley AJ; Zinman B
J Clin Endocrinol Metab; 2010 Sep; 95(9):4345-53. PubMed ID: 20631030
[TBL] [Abstract][Full Text] [Related]
14. Cross-sectional and longitudinal associations of apolipoprotein A1 and B with glycosylated hemoglobin in Chinese adults.
Dong H; Ni W; Bai Y; Yuan X; Zhang Y; Zhang H; Sun Y; Xu J
Sci Rep; 2022 Feb; 12(1):2751. PubMed ID: 35177752
[TBL] [Abstract][Full Text] [Related]
15. The relationship between high-sensitivity C-reactive protein and ApoB, ApoB/ApoA1 ratio in general population of China.
Xu W; Li R; Zhang S; Gong L; Wang Z; Ren W; Xia C; Li Q
Endocrine; 2012 Aug; 42(1):132-8. PubMed ID: 22246850
[TBL] [Abstract][Full Text] [Related]
16. The apolipoprotein B/A1 ratio is associated with reactive oxygen metabolites and endothelial dysfunction in statin-treated patients with coronary artery disease.
Emoto T; Sawada T; Morimoto N; Tenjin T; Wakimoto T; Ikeda F; Sato C; Terashita D; Mizoguchi T; Mizuguchi T; Okamoto H; Matsuo Y; Kim SK; Takarada A; Yokoyama M
J Atheroscler Thromb; 2013; 20(7):623-9. PubMed ID: 23665841
[TBL] [Abstract][Full Text] [Related]
17. Associations of serum apolipoprotein A1, B levels and their ratio with blood pressure in Chinese adults with coronary artery disease.
Dong H; Yang X; Zhang Y; Hu P; Liu Y; Liang S
Blood Press Monit; 2021 Dec; 26(6):401-406. PubMed ID: 34074807
[TBL] [Abstract][Full Text] [Related]
18. Apolipoprotein B-to-A1 ratio as a predictor of acute ischemic nonembolic stroke in elderly subjects.
Kostapanos MS; Christogiannis LG; Bika E; Bairaktari ET; Goudevenos JA; Elisaf MS; Milionis HJ
J Stroke Cerebrovasc Dis; 2010; 19(6):497-502. PubMed ID: 20538481
[TBL] [Abstract][Full Text] [Related]
19. Stiffness of the abdominal aorta in beta-thalassemia major patients related with body iron load.
Ulger Z; Aydinok Y; Gurses D; Levent E; Ozyurek AR
J Pediatr Hematol Oncol; 2006 Oct; 28(10):647-52. PubMed ID: 17023824
[TBL] [Abstract][Full Text] [Related]
20. Consistency of extended-release niacin/laropiprant effects on Lp(a), ApoB, non-HDL-C, Apo A1, and ApoB/ApoA1 ratio across patient subgroups.
Bays HE; Shah A; Lin J; Sisk CM; Dong Q; Maccubbin D
Am J Cardiovasc Drugs; 2012 Jun; 12(3):197-206. PubMed ID: 22500948
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
